Silicon Investor (SI) -- The First Internet Community

STOCKTALK

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor. We ask that you disable ad blocking while on Silicon Investor in the best interests of our community. If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.

Biotech / Medical : Pharmacia Corp. a future biotech powerhouse? -- Ignore unavailable to you. Want to Upgrade?

To: Jack Hartmann who wrote (3)	4/25/2000 4:28:00 PM
From: Jack Hartmann	Read Replies (1) \| Respond to of 35

Pharmacia Earnings Strengthen, Meeting Expectations By Carolyn Koo TheStreet.com/NYTimes.com Staff Reporter 4/25/00 1:40 PM ET Pharmacia (PHA:NYSE - news - boards) reported a 31% increase in first-quarter earnings Tuesday, helped by strong sales of the company's main drugs. The results, excluding merger-releated costs, met Wall Street expectations. The company, based in Peapack, N.J., was formed from the merger of pharmaceutical maker Pharmacia & Upjohn and life sciences behemoth Monsanto on March 31. Pharmacia, now one of the top drug makers in the world, said that for the quarter ended March 31, earnings, excluding a $461 million charge for costs relating to the merger, rose to $425 million, or 33 cents a diluted share, from $324 million, or 25 cents a share, a year earlier. The consensus estimate of analysts polled by First Call/Thomson Financial was 33 cents. Including the charge for the merger and other special items, the company reported earnings of $98 million, or 7 cents a diluted share. The figures also include a contribution to charity of $100 million from the proceeds of businesses divested by Monsanto as well as a $58 million gain from discontinued operations. Revenue rose 5% to $4.29 billion from $4.10 billion a year ago, due to pharmaceutical sales that increased 10%, to $2.85 billion. Blockbuster arthritis treatment Celebrex and glaucoma therapy Xalatan accounted for the biggest percentage, with Celebrex sales totaling $534 million and Xalatan $161 million. Net sales for Monsanto's agricultural business -- which account for about one-third of Pharmacia's revenue -- fell 2%, mostly because of a 5% drop in revenue of the Roundup herbicide. Shares of Pharmacia fell 3 5/8, or 6%, to 54 7/16 in midday Tuesday trading ********* Haven't read the earning report, but selloff on news means it may be cheaper this week. Jack